NEW YORK (GenomeWeb) – Agilent Technologies reported after the close of the market Wednesday that its third quarter revenues increased 3 percent year over year, with growth in its CrossLab Group and Diagnostics and Genomic Group partially offset by a decline for its Life Sciences and Applied Markets Group.

For the three months ended July 31, 2016, Agilent reported total revenues of $1.04 billion, up from $1.01 billion in the third quarter of 2015. It fell just shy of the average analyst estimate for revenues of $1.05 billion.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.

The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.

Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.

In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.